The IASLC Targeted Therapies Meeting has historically been a very interactive, fast-paced meeting that highlights the latest and most innovative anticancer drugs, initially focused on targeted agents but in recent years, extending to immunotherapy. In this Lung Cancer Considered podcast hosts Dr. Narjust Duma and Dr. Stephen Liu lead a wide-ranging discussion of the meeting with three lung cancer experts who attended the meeting: Dr. Lecia Sequist is a thoracic medical oncologist at Massachusetts General Hospital, the Landry Family Professor of Medicine at Harvard Medical School, the Director of the Center for Innovation in Early Cancer Detection and a board member of the IASLC. Ivy Elkins was diagnosed with Stage IV lung cancer in Dec 2013 as a healthy 47-year-old, Ivy was found to have an EGFR mutation and has spent the years since her diagnosis educating herself and advocating for herself and those within the lung cancer community. Ivy is a patient advocate and co-founder of the EGFR Resisters Lung Cancer Patient Group. Dr. Charu Aggarwal is a thoracic medical oncologist at the Hospital of the University of Pennsylvania and the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at the University of Pennsylvania.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related